Abstract:Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and has extremely high morbidity and mortality. Although many existing studies have focused on the identification of biomarkers, little information has been uncovered regarding the PBMC RNA profile of HCC. We attempted to create a profile throughout using expression of peripheral blood mononuclear cell (PBMC) RNA using RNA-seq technology and compared the transcriptome between HCC patients and healthy controls. Seventeen patients and 17 matched healthy controls were included in this study, and PBMC RNA was sequenced from all samples. Sequencing data were analyzed using bioinformatics tools, and quantitative reverse transcription PCR (qRT-PCR) was used for selected validation of DEGs. A total of 1,578 dysregulated genes were found in the PBMC samples, including 1,334 upregulated genes and 244 downregulated genes. GO enrichment and KEGG studies revealed that HCC is closely linked to differentially expressed genes (DEGs) implicated in the immune response. Expression of 6 selected genes (SELENBP1, SLC4A1, SLC26A8, HSPA8P4, CALM1, and RPL7p24) was confirmed by qRT-PCR, and higher sensitivity and specificity were obtained by ROC analysis of the 6 genes. CALM1 was found to gradually decrease as tumors enlarged. Nearly the opposite expression modes were obtained when compared to tumor sequencing data. Immune cell populations exhibited significant differences between HCC and controls. These findings suggest a potential biomarker for the diagnosis of HCC. This study provides new perspectives for liver cancer development and possible future successful clinical diagnosis.

What problem does this paper attempt to address?

The problem this paper attempts to address is the identification of potential biomarkers for hepatocellular carcinoma (HCC). Specifically, the researchers analyzed the RNA expression profiles of peripheral blood mononuclear cells (PBMC) to compare the differentially expressed genes (DEGs) between HCC patients and healthy controls, aiming to discover biomarkers that can be used for early diagnosis of HCC. ### Background - **High incidence and mortality of HCC**: HCC is a common malignant tumor with extremely high incidence and mortality rates. - **Limitations of existing biomarkers**: Currently used biomarkers such as alpha-fetoprotein (AFP) lack sufficient sensitivity and specificity for early diagnosis of HCC, leading to many patients being diagnosed at a late stage with limited treatment options. - **Research gap in PBMC RNA**: Although many studies have focused on identifying biomarkers for HCC, there is limited information on the RNA expression profiles of PBMCs in HCC patients. ### Research Objectives - **Create PBMC RNA expression profiles**: Utilize RNA sequencing technology (RNA-seq) to create PBMC RNA expression profiles for HCC patients and healthy controls. - **Identify differentially expressed genes**: Use bioinformatics tools to analyze sequencing data and identify differentially expressed genes between HCC patients and healthy controls. - **Validate candidate genes**: Validate selected differentially expressed genes using quantitative reverse transcription PCR (qRT-PCR). - **Evaluate diagnostic value**: Assess the sensitivity and specificity of these genes in HCC diagnosis through receiver operating characteristic (ROC) curve analysis. ### Main Findings - **Differentially expressed genes**: A total of 1,578 differentially expressed genes were identified, including 1,334 upregulated genes and 244 downregulated genes. - **Functional enrichment analysis**: GO enrichment and KEGG pathway analysis indicated that the differentially expressed genes related to HCC are closely associated with immune response. - **Validation results**: Six candidate genes (SELENBP1, SLC4A1, SLC26A8, HSPA8P4, CALM1, and RPL7p24) were validated by qRT-PCR, with 5 genes showing significantly different expression in HCC patients. - **Special performance of CALM1**: The expression of the CALM1 gene gradually decreased in HCC patients and further decreased with tumor growth. ### Conclusion - **Potential biomarkers**: These findings suggest that certain genes in the PBMC RNA expression profiles (especially CALM1) may serve as potential biomarkers for early diagnosis of HCC. - **Clinical significance**: This study provides new insights into the development of liver cancer and lays the foundation for further successful clinical diagnosis.

RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma

Transcriptome Profiling of Hepatocellular Carcinoma Uncovers Multi-Types of Dysregulated ncRNAs

Identification of Long Noncoding RNAs Biomarkers in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Profiling, clinicopathological correlation and functional validation of specific long non-coding RNAs for hepatocellular carcinoma

Identification of the Pathogenic Biomarkers for Hepatocellular Carcinoma Based on RNA-seq Analyses

Genes Expression Profiling of Peripheral Blood Cells of Patients with Hepatocellular Carcinoma

Rna-Seq Analyses Generate Comprehensive Transcriptomic Landscape And Reveal Complex Transcript Patterns In Hepatocellular Carcinoma

Integrated Bioinformatic Analysis of RNA Binding Proteins in Hepatocellular Carcinoma

Noncoding RNAs Serve As Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma.

Coupled scRNA-seq and Bulk-seq reveal the role of HMMR in hepatocellular carcinoma

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma

High-throughput sequencing-based analysis of gene expression of hepatitis B virus infection-associated human hepatocellular carcinoma

The Potential of the lncRNAs ADAMTSL4-AS1, AC067931 and SOCS2-AS1 in Peripheral Blood Mononuclear Cells as Novel Diagnostic Biomarkers for Hepatitis B Virus-Associated Hepatocellular Carcinoma

Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients

Profiling and Integrated Analysis of Differentially Expressed MicroRNAs as Novel Biomarkers of Hepatocellular Carcinoma

Microarray Expression Profiling of microRNAs Reveals Potential Biomarkers for Hepatocellular Carcinoma.

Leveraging single-cell RNA-seq for uncovering naïve B cells associated with better prognosis of hepatocellular carcinoma

Identification of Novel Enhancer RNA Biomarkers and Corresponding Prognostic Signatures of Hepatocellular Carcinoma

Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma

Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma